Enhancing the structural stability of P29-targeted monoclonal antibodies via β-hydroxybutyrylation modification improves their therapeutic performance in alveolar echinococcosis

Our results establish a novel connection between protein engineering and antiparasitic therapy, illustrating that Kbhb modification not only augments the efficacy of anti-AE antibodies but also offers a versatile strategy for enhancing antibody stability and half-life. This offers a potential strategy for developing new treatments against neglected zoonotic diseases via tailored post-translational modifications.